Peptides and their uses
Specific peptides with defined sequences address the challenge of identifying physiologically active blood peptides, offering anti-obesity, inflammatory, and arteriosclerosis treatments, and therapeutic screening methods.
Patent Information
- Application Number
- JP2020217311
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-12-25
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2040-12-25
AI Technical Summary
Conventional mass spectrometry techniques are inadequate for identifying physiologically active peptides in blood due to the presence of high molecular weight proteins, limiting the discovery of human bioactive peptides, particularly those with potential therapeutic applications such as anti-obesity agents, inflammatory disease treatments, tumor therapies, and arteriosclerosis agents.
Identification and development of specific peptides with defined amino acid sequences (SEQ ID NOs: 1 to 5) that exhibit activities like suppressing feeding, inducing inflammatory cytokine expression, or promoting arteriosclerosis when administered to mammals, along with methods to screen for therapeutic agents by identifying receptors and inhibitors.
The peptides provide effective anti-obesity drugs, therapeutic agents for inflammatory diseases and tumors, and agents for accelerating or treating arteriosclerosis, leveraging their natural presence in human blood and safety for human administration.
Smart Images

Figure 0007589982000002 
Figure 0007589982000003 
Figure 0007589982000004
Abstract
Description
[Technical Field]
[0001] The present invention relates to peptides and uses thereof. [Background technology]
[0002] Blood contains a huge amount of high-molecular-weight proteins. Therefore, it has been impossible to identify bioactive peptides present in blood using conventional mass spectrometry alone. In the past 20 years, very few bioactive peptides have been discovered in humans.
[0003] The inventors previously developed a plasma peptidome analysis technique, which had previously been considered difficult, and succeeded in determining the structures of the large number of small molecular weight peptides present in human plasma (see Non-Patent Documents 1 and 2). [Prior art documents] [Non-patent literature]
[0004] [Non-Patent Document 1] Kawashima Y., et al., High-yield peptide-extraction method for the discovery of subnanomolar biomarkers from small serum samples, J Proteome Res, 9 (4), 1694-1705, 2010. [Non-patent document 2] Saito T., et al., Establishment and application of a high-quality comparative analysis strategy for the discovery and small-scale validation of low-abundance biomarker peptides in serum based on an optimized novel peptide extraction method, J Electrophoresis, 57, 1, 1-9, 2013. Summary of the Invention [Problem to be solved by the invention]
[0005] The present invention aims to provide novel physiologically active peptides present in human blood. More specifically, the present invention aims to provide an anti-obesity drug; an inducer of the expression of inflammatory cytokines, chemokines, cell growth factors, or angiogenesis-promoting factors through activation of NF-κB signaling in vascular smooth muscle cells, vascular endothelial cells, or macrophage cells; a method for screening therapeutic agents for inflammatory diseases or tumors; therapeutic agents for inflammatory diseases or tumors; and an agent for promoting and treating arteriosclerosis. [Means for solving the problem]
[0006] The present invention includes the following aspects. [1] An anti-obesity drug containing as an active ingredient: (i) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1; (ii) a peptide consisting of an amino acid sequence set forth in SEQ ID NO: 1 in which 1 to 3 amino acids have been deleted, substituted or added, and which has the activity of suppressing eating or drinking when administered to a mammal; (iii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 2; or (iv) a peptide consisting of an amino acid sequence set forth in SEQ ID NO: 2 in which 1 to 3 amino acids have been deleted, substituted or added, and which has the activity of suppressing eating or drinking when administered to a mammal. [2] (v) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 3; (vi) a peptide consisting of an amino acid sequence in which 1 to 3 amino acids are deleted, substituted or added in the amino acid sequence set forth in SEQ ID NO: 3, and which has the activity of inducing the expression of inflammatory cytokines, chemokines, cell growth factors or angiogenesis promoting factors through the activation of NF-κB signaling when contacted with vascular smooth muscle cells, vascular endothelial cells or macrophage cells; (vii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4; or (viii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4. An inducer of expression of inflammatory cytokines, chemokines, cell growth factors or angiogenesis promoting factors through activation of NF-κB signaling in vascular smooth muscle cells, vascular endothelial cells or macrophage cells, the active ingredient of which is a peptide consisting of an amino acid sequence in which 1 to 3 amino acids have been deleted, substituted or added, and which has the activity of inducing the expression of inflammatory cytokines, chemokines, cell growth factors or angiogenesis promoting factors through activation of NF-κB signaling when brought into contact with vascular smooth muscle cells, vascular endothelial cells or macrophage cells. [3] (v) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 3; (vi) a peptide consisting of an amino acid sequence in which 1 to 3 amino acids are deleted, substituted or added in the amino acid sequence set forth in SEQ ID NO: 3, and which has the activity of inducing the expression of inflammatory cytokines, chemokines, cell growth factors or angiogenesis promoting factors through the activation of NF-κB signaling when contacted with vascular smooth muscle cells, vascular endothelial cells or macrophage cells; (vii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4; or (viii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4. A method for screening therapeutic agents for inflammatory diseases or tumors, comprising the steps of: identifying a receptor for a peptide consisting of an amino acid sequence in which 1 to 3 amino acids have been deleted, substituted, or added, and which has the activity of inducing the expression of inflammatory cytokines, chemokines, cell growth factors, or angiogenesis promoting factors through the activation of NF-κB signaling when contacted with vascular smooth muscle cells, vascular endothelial cells, or macrophage cells; and screening test substances to identify an inhibitor of the receptor, wherein the inhibitor is a therapeutic agent for inflammatory diseases or tumors. [4] (v) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 3; (vi) a peptide consisting of an amino acid sequence set forth in SEQ ID NO: 3 in which 1 to 3 amino acids are deleted, substituted or added, and which has the activity of inducing the expression of inflammatory cytokines, chemokines, cell growth factors or angiogenesis promoting factors through the activation of NF-κB signaling when contacted with vascular smooth muscle cells, vascular endothelial cells or macrophage cells; (vii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4; or (viii) a peptide consisting of an amino acid sequence set forth in SEQ ID NO: 4 in which 1 to 3 amino acids are deleted, substituted or added, and and a method for screening a therapeutic agent for an inflammatory disease or tumor, the method comprising the steps of culturing vascular smooth muscle cells, vascular endothelial cells, or macrophage cells in the presence of a peptide having activity of inducing the expression of an inflammatory cytokine, a chemokine, a cell growth factor, or an angiogenesis promoting factor through activation of NF-κB signaling when contacted with vascular smooth muscle cells, vascular endothelial cells, or macrophage cells, and measuring the expression level of the inflammatory cytokine, chemokine, cell growth factor, or angiogenesis promoting factor in the cells, wherein a significant decrease in the expression level compared to that in the absence of the test substance indicates that the test substance is a therapeutic agent for an inflammatory disease or tumor. [5] A therapeutic agent for inflammatory diseases or tumors, comprising as an active ingredient an antibody or a fragment thereof against: (v) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 3; (vi) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 3 in which 1 to 3 amino acids are deleted, substituted or added, and which has the activity of inducing the expression of inflammatory cytokines, chemokines, cell growth factors or angiogenesis promoting factors through the activation of NF-κB signaling when contacted with vascular smooth muscle cells, vascular endothelial cells or macrophage cells; (vii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4; or (viii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4 in which 1 to 3 amino acids are deleted, substituted or added, and which has the activity of inducing the expression of inflammatory cytokines, chemokines, cell growth factors or angiogenesis promoting factors through the activation of NF-κB signaling when contacted with vascular smooth muscle cells, vascular endothelial cells or macrophage cells. [6] (ix) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 5, or (x) an amino acid sequence in which 1 to 3 amino acids are deleted, substituted or added in the amino acid sequence set forth in SEQ ID NO: 5, and which is an ApoE - / - An arteriosclerosis promoter, the active ingredient of which is a peptide that has the activity of promoting arteriosclerosis when administered to mice. [7] (ix) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 5, or (x) an amino acid sequence in which 1 to 3 amino acids are deleted, substituted or added in the amino acid sequence set forth in SEQ ID NO: 5, and which is an ApoE - / - A method for screening an arteriosclerosis therapeutic agent, comprising: a step of identifying a receptor for a peptide that has the activity of promoting arteriosclerosis when administered to a mouse; and a step of screening a test substance to identify an inhibitor of the receptor, wherein the inhibitor is an arteriosclerosis therapeutic agent. [8] (ix) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 5, or (x) an amino acid sequence in which 1 to 3 amino acids are deleted, substituted or added in the amino acid sequence set forth in SEQ ID NO: 5, and which is an ApoE - / -A method for screening for an agent for treating arteriosclerosis, comprising the steps of culturing vascular smooth muscle cells, vascular endothelial cells, or macrophage cells in the presence of a peptide having an activity of promoting arteriosclerosis when administered to a mouse, and a test substance, and measuring the expression level of inflammatory cytokines or arteriosclerosis-promoting factors in the cells, wherein a significant decrease in the expression level compared to that in the absence of the test substance indicates that the test substance is an agent for treating arteriosclerosis. [9] (ix) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 5, or (x) an amino acid sequence in which 1 to 3 amino acids are deleted, substituted or added in the amino acid sequence set forth in SEQ ID NO: 5, and which is an ApoE - / - An agent for treating arteriosclerosis, the active ingredient of which is an antibody or a fragment thereof against a peptide that has the activity of promoting arteriosclerosis when administered to mice. [Effects of the Invention]
[0007] The present invention provides novel physiologically active peptides present in human blood. More specifically, it provides anti-obesity drugs; inducers of inflammatory cytokines, chemokines, cell growth factors, or angiogenesis-promoting factors through activation of NF-κB signaling in vascular smooth muscle cells, vascular endothelial cells, and macrophages; methods for screening therapeutic agents for inflammatory diseases or tumors; therapeutic agents for inflammatory diseases or tumors; and agents for promoting and treating arteriosclerosis. [Brief explanation of the drawings]
[0008] [Figure 1] 1(a) and 1(b) are graphs showing the results of Experimental Example 2. 1(c) to 1(f) are confocal micrographs showing the results of Experimental Example 2. [Figure 2] 6(a) and 6(b) are graphs showing the results of Experimental Example 3. [Figure 3] 1(a) and 1(b) are photographs showing the results of Western blotting in Experimental Example 4. 1(c) to 1(e) are fluorescent micrographs showing the results of immunostaining in Experimental Example 4. [Figure 4]6(a) and 6(b) are graphs showing the results of Experimental Example 5. [Figure 5] 6(a) to 6(f) are graphs showing the results of Experimental Example 6. [Figure 6] Fluorescence micrographs (a) to (e), (a') to (e'), and (a'') to (e'') show the results of immunostaining in Experimental Example 8. [Figure 7] 10(a) to 10(f) are confocal micrographs showing the results of Experimental Example 9. [Figure 8] 10(a) to 10(c) are graphs showing the results of Experimental Example 10. [Figure 9] 10(a) to 10(c) are graphs showing the results of Experimental Example 11. [Figure 10] 10(a) to 10(d) are confocal micrographs showing the results of Experimental Example 12. [Figure 11] 10(a) to 10(d) are micrographs showing the results of Experimental Example 13. [Figure 12] (a) to (d) are macroscopic tissue specimens showing the results of Experimental Example 14. (e) to (l) are micrographs showing the results of Experimental Example 14. [Figure 13] 6(a) and 6(b) are graphs showing the results of Experimental Example 14. DETAILED DESCRIPTION OF THE INVENTION
[0009] [Anti-obesity drug] In one embodiment, the present invention provides an anti-obesity drug containing as an active ingredient: (i) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1; (ii) a peptide consisting of an amino acid sequence set forth in SEQ ID NO: 1 in which 1 to 3 amino acids have been deleted, substituted or added, and which has the activity of suppressing food intake or water drinking when administered to a mammal; (iii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 2; or (iv) a peptide consisting of an amino acid sequence set forth in SEQ ID NO: 2 in which 1 to 3 amino acids have been deleted, substituted or added, and which has the activity of suppressing food intake or water drinking when administered to a mammal.
[0010] As described later in the Examples, the inventors have demonstrated that a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1 (a peptide consisting of amino acids 279 to 295 in the amino acid sequence of human sprabasin; hereinafter, sometimes referred to as "SBSN_HUMAN[279-295]") and a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 2 (a peptide consisting of amino acids 448 to 462 in the amino acid sequence of human proangiotensinogen; hereinafter, sometimes referred to as "ANGT_HUMAN[448-462]") have potent food-suppressing activity in experiments using mice.
[0011] These peptides have a strong appetite-suppressing effect far superior to that of GLP-1 agonists, which have become the second-line drugs for type 2 diabetes worldwide. Therefore, they can be used as anti-obesity drugs, which have long been sought after internationally, to treat type 2 diabetes and other conditions.
[0012] Furthermore, these peptides are naturally present in human blood and are therefore safe to administer to humans.
[0013] As long as the peptides of this embodiment have the activity, SBSN_HUMAN[279-295] (SEQ ID NO: 1) and ANGT_HUMAN[448-462] (SEQ ID NO: 2) may have deletions, substitutions, or additions of 1 to 3 amino acids. Furthermore, these peptides may be in the form of pharmaceutically acceptable salts or solvates. Examples of salts include trifluoroacetic acid (TFA) salts, acetate salts, and hydrochloride salts. Examples of solvates include hydrates and organic solvent solvates.
[0014] [Inducers of inflammatory cytokines, chemokines, cell growth factors, or angiogenesis-promoting factors] In one embodiment, the present invention provides (v) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 3; (vi) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 3 in which 1 to 3 amino acids are deleted, substituted or added, and which has the activity of inducing the expression of inflammatory cytokines, chemokines, cell growth factors or angiogenesis promoting factors through the activation of NF-κB signaling when contacted with vascular smooth muscle cells, vascular endothelial cells or macrophage cells; (vii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4; or (viii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4 Provided is an inducer of expression of inflammatory cytokines, chemokines, cell growth factors or angiogenesis-promoting factors through activation of NF-κB signaling in vascular smooth muscle cells, vascular endothelial cells or macrophage cells, the active ingredient of which is a peptide consisting of an amino acid sequence in which 1 to 3 amino acids have been deleted, substituted or added, and which has the activity of inducing the expression of inflammatory cytokines, chemokines, cell growth factors or angiogenesis-promoting factors through activation of NF-κB signaling when brought into contact with vascular smooth muscle cells, vascular endothelial cells or macrophage cells.
[0015] As described later in the Examples, the inventors have demonstrated that when a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 3 (a peptide consisting of amino acids at positions 225 to 237 in the amino acid sequence of human suprabasin; hereinafter, sometimes referred to as "SBSN_HUMAN[225-237]") or a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4 (a peptide consisting of amino acids at positions 243 to 259 in the amino acid sequence of human suprabasin; hereinafter, sometimes referred to as "SBSN_HUMAN[243-259]") is brought into contact with vascular smooth muscle cells, vascular endothelial cells, or macrophage cells, the peptide induces the expression of inflammatory cytokines, chemokines, cell growth factors, and angiogenesis-promoting factors through activation of NF-κB signaling.
[0016] Therefore, these peptides can be used as research reagents, etc., as agents for inducing the expression of inflammatory cytokines, chemokines, cell growth factors, or angiogenesis-promoting factors through activation of NF-κB signaling in vascular smooth muscle cells, vascular endothelial cells, or macrophage cells.
[0017] As long as the peptides of this embodiment have the activity, SBSN_HUMAN[225-237] (SEQ ID NO: 3) and SBSN_HUMAN[243-259] (SEQ ID NO: 4) may have deletions, substitutions, or additions of 1 to 3 amino acids. Furthermore, these peptides may be in the form of pharmaceutically acceptable salts or solvates. Examples of salts include trifluoroacetic acid (TFA) salts, acetate salts, and hydrochloride salts. Examples of solvates include hydrates and organic solvent solvates.
[0018] [Method for screening therapeutic agents for inflammatory diseases or tumors] (First embodiment) In one embodiment, the present invention provides (v) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 3; (vi) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 3 in which 1 to 3 amino acids are deleted, substituted or added, and which has the activity of inducing the expression of inflammatory cytokines, chemokines, cell growth factors or angiogenesis promoting factors through the activation of NF-κB signaling when contacted with vascular smooth muscle cells, vascular endothelial cells or macrophage cells; (vii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4; or (viii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4 The present invention provides a method for screening therapeutic agents for inflammatory diseases or tumors, comprising the steps of: identifying a receptor for a peptide consisting of an amino acid sequence in which 1 to 3 amino acids have been deleted, substituted, or added, and which has the activity of inducing the expression of inflammatory cytokines, chemokines, cell growth factors, or angiogenesis promoting factors through the activation of NF-κB signaling when contacted with vascular smooth muscle cells, vascular endothelial cells, or macrophage cells; and screening test substances to identify an inhibitor of the receptor, wherein the inhibitor is a therapeutic agent for inflammatory diseases or tumors.
[0019] As described later in the Examples, the inventors have demonstrated that SBSN_HUMAN[225-237] (SEQ ID NO: 3) and SBSN_HUMAN[243-259] (SEQ ID NO: 4) bind to vascular smooth muscle cells, indicating that receptors exist for these peptides.
[0020] The above-mentioned SBSN_HUMAN[225-237] (SEQ ID NO: 3), SBSN_HUMAN[243-259] (SEQ ID NO: 4), and inhibitors of the receptors of these mutant peptides can be used as therapeutic agents for diseases caused by inflammatory cytokines, chemokines, cell growth factors, or angiogenesis-promoting factors, i.e., inflammatory diseases such as cytokine storms such as rheumatoid arthritis and severe COVID-19 pneumonia; tumors; and the like.
[0021] Therefore, in one embodiment, the present invention provides a method for screening a therapeutic agent for an inflammatory disease or tumor, comprising the steps of identifying a receptor for the above-mentioned peptide and screening a test substance to identify an inhibitor of the receptor, wherein the inhibitor is a therapeutic agent for the inflammatory disease or tumor.
[0022] The test substance is not particularly limited, and examples thereof include natural compound libraries, synthetic compound libraries, existing drug libraries, metabolite libraries, antibody libraries, and the like.
[0023] Receptor identification can be performed, for example, as follows. First, membrane proteins from vascular smooth muscle cells are extracted and mixed with liposomes to produce liposomes with embedded membrane proteins. The liposomes are then passed through a membrane, and those with a diameter of, for example, 200 nm or less are collected. These are used as a membrane protein library, and liposomes that exhibit binding to the above peptides are collected. Receptor proteins can then be identified by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), band excision, trypsin digestion, liquid chromatography (LC), and mass spectrometry (MS / MS), etc.
[0024] Examples of receptor inhibitors include substances that inhibit the binding of the receptor to the above peptide, and substances that inhibit signal transduction after the receptor and the above peptide bind to each other.
[0025] Substances that inhibit the binding of the receptor to the peptide include decoy receptors, fragment peptides of the peptides, antibodies against the peptides or fragments thereof, etc. Examples of decoy receptors include solubilized receptors, and more specifically, fusion proteins of receptors with antibody constant regions.
[0026] (Second embodiment) In one embodiment, the present invention relates to (v) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 3; (vi) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 3 in which 1 to 3 amino acids are deleted, substituted or added, and which has the activity of inducing the expression of inflammatory cytokines, chemokines, cell growth factors or angiogenesis promoting factors through the activation of NF-κB signaling when contacted with vascular smooth muscle cells, vascular endothelial cells or macrophage cells; (vii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4; or (viii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4 in which 1 to 3 amino acids are deleted, substituted or added. The present invention provides a method for screening for a therapeutic agent for an inflammatory disease or tumor, comprising the steps of culturing vascular smooth muscle cells, vascular endothelial cells, or macrophage cells in the presence of a test substance and a peptide having an activity of inducing the expression of an inflammatory cytokine, a chemokine, a cell growth factor, or an angiogenesis promoting factor through the activation of NF-κB signaling when contacted with vascular smooth muscle cells, vascular endothelial cells, or macrophage cells, and measuring the expression level of the inflammatory cytokine, chemokine, cell growth factor, or angiogenesis promoting factor in the cells, wherein a significant decrease in the expression level compared to that in the absence of the test substance indicates that the test substance is a therapeutic agent for an inflammatory disease or tumor.
[0027] As described later in the Examples, the inventors have demonstrated that SBSN_HUMAN[225-237] (SEQ ID NO: 3) and SBSN_HUMAN[243-259] (SEQ ID NO: 4) act on vascular smooth muscle cells, vascular endothelial cells, or macrophages to induce the expression of inflammatory cytokines, chemokines, cell growth factors, and angiogenesis-promoting factors through the activation of NF-κB signaling. Therefore, test substances that suppress the induction of the expression of these factors can be used as therapeutic agents for inflammatory diseases or tumors.
[0028] That is, the present invention provides a method for screening for therapeutic agents for inflammatory diseases or tumors, comprising the steps of culturing vascular smooth muscle cells, vascular endothelial cells, or macrophage cells in the presence of the above-mentioned SBSN_HUMAN[225-237] (SEQ ID NO: 3), SBSN_HUMAN[243-259] (SEQ ID NO: 4), or mutant peptides thereof, and a test substance, and measuring the expression levels of inflammatory cytokines, chemokines, cell growth factors, or angiogenesis promoting factors in the cells, wherein a significant decrease in the expression levels compared to those in the absence of the test substance indicates that the test substance is a therapeutic agent for inflammatory diseases or tumors. The method of the second embodiment can also be used to screen for therapeutic agents for inflammatory diseases or tumors.
[0029] The test substances are the same as those described above. Examples of inflammatory cytokines, chemokines, cell growth factors, or angiogenesis-promoting factors include vascular endothelial growth factor a (VEGFa), Dickkopf-related protein 1 (DKK1), endoglin, urokinase plasminogen activator receptor (uPAR), granulocyte macrophage colony-stimulating factor (GM-CSF), vascular cell adhesion molecule 1 (VCAM1), cystatin C, hepatocyte growth factor (HGF), osteopontin (OPN), interleukin-6 (IL-6), angiogenin, etc.
[0030] [Therapeutic agent for inflammatory diseases or tumors] In one embodiment, the present invention provides a therapeutic agent for inflammatory diseases or tumors, the active ingredient of which is an antibody or a fragment thereof against: (v) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 3; (vi) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 3 in which 1 to 3 amino acids have been deleted, substituted, or added, and which has the activity of inducing the expression of inflammatory cytokines, chemokines, cell growth factors, or angiogenesis promoting factors through the activation of NF-κB signaling when contacted with vascular smooth muscle cells, vascular endothelial cells, or macrophage cells; (vii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4; or (viii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4 in which 1 to 3 amino acids have been deleted, substituted, or added, and which has the activity of inducing the expression of inflammatory cytokines, chemokines, cell growth factors, or angiogenesis promoting factors through the activation of NF-κB signaling when contacted with vascular smooth muscle cells, vascular endothelial cells, or macrophage cells.
[0031] As described later in the Examples, the inventors have demonstrated that SBSN_HUMAN[225-237] (SEQ ID NO: 3) and SBSN_HUMAN[243-259] (SEQ ID NO: 4) act on vascular smooth muscle cells, vascular endothelial cells, or macrophage cells to induce the expression of inflammatory cytokines, chemokines, cell growth factors, and angiogenesis-promoting factors through activation of NF-κB signaling.
[0032] Therefore, antibodies or fragments thereof against SBSN_HUMAN[225-237] (SEQ ID NO: 3), SBSN_HUMAN[243-259] (SEQ ID NO: 4), or their mutant peptides inhibit the binding of these peptides to their receptors and suppress the induction of expression of proinflammatory cytokines, chemokines, cell growth factors, or angiogenesis-promoting factors through activation of NF-κB signaling in vascular smooth muscle cells, vascular endothelial cells, or macrophages. Examples of antibody fragments include F(ab')2, Fab', Fab, Fv, and scFv. Such antibodies or fragments thereof can be used as therapeutic agents for inflammatory diseases or tumors.
[0033] The antibody is preferably a human antibody. Examples of human antibodies include chimeric antibodies, humanized antibodies, and fully human antibodies. Here, a chimeric antibody refers to an antibody in which the variable regions are derived from a non-human animal and at least a portion of the constant region is derived from a human antibody. A humanized antibody refers to an antibody in which only the complementarity-determining regions of the heavy and light chains are derived from a non-human animal and the constant and framework regions are derived from a human antibody. A fully human antibody refers to an antibody in which the entire antibody, including the complementarity-determining regions, is derived from a human.
[0034] If the antibody or fragment thereof is a human antibody or fragment thereof, it will have low immunogenicity when administered to humans, and side effects such as anaphylactic shock can be suppressed.
[0035] [Arteriosclerosis promoter] In one embodiment, the present invention provides (ix) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 5, or (x) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 5 in which 1 to 3 amino acids have been deleted, substituted, or added, and which is an ApoE - / - The present invention provides an arteriosclerosis promoter, which contains as an active ingredient a peptide that has the activity of promoting arteriosclerosis when administered to mice.
[0036] As will be described later in the Examples, the inventors administered a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 5 (a peptide consisting of amino acids 22 to 51 in the amino acid sequence of human glucose-dependent insulinotropic polypeptide (GIP), hereinafter sometimes referred to as "GIP_HUMAN[22-51]") to a mouse model of atherosclerosis, ApoE - / - It was revealed that when administered to mice, arteriosclerosis was significantly promoted.
[0037] Therefore, GIP_HUMAN[22-51] (SEQ ID NO: 5) can be used as an arteriosclerosis promoter in research reagents, etc. As long as it has the activity of this embodiment, the peptide of GIP_HUMAN[22-51] (SEQ ID NO: 5) may have deletion, substitution, or addition of 1 to 3 amino acids. Furthermore, these peptides may be in the form of pharmaceutically acceptable salts or solvates. Examples of salts include trifluoroacetic acid (TFA) salts, acetate salts, and hydrochlorides. Examples of solvates include hydrates and organic solvent solvates.
[0038] [Method for screening arteriosclerosis treatment agents] (First embodiment) In one embodiment, the present invention provides (ix) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 5, or (x) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 5 in which 1 to 3 amino acids have been deleted, substituted, or added, and which is an ApoE - / -The present invention provides a method for screening an arteriosclerosis therapeutic agent, comprising the steps of: identifying a receptor for a peptide that has the activity of promoting arteriosclerosis when administered to a mouse; and screening test substances to identify an inhibitor of the receptor, wherein the inhibitor is an arteriosclerosis therapeutic agent.
[0039] As described later in the Examples, the inventors administered GIP_HUMAN[22-51] (SEQ ID NO: 5) to a mouse model of atherosclerosis, ApoE - / - It was revealed that administration of GIP_HUMAN[22-51] (SEQ ID NO: 5) to mice significantly promoted arteriosclerosis. Therefore, inhibitors of the receptor for GIP_HUMAN[22-51] (SEQ ID NO: 5) or its mutant peptides could be used as therapeutic agents for arteriosclerosis.
[0040] Specifically, the present invention provides a method for screening for therapeutic agents for arteriosclerosis, comprising the steps of identifying a receptor for GIP_HUMAN[22-51] (SEQ ID NO: 5) and screening test substances to identify an inhibitor of the receptor, wherein the inhibitor is an agent for treating arteriosclerosis. The test substance, the identification of the receptor, and the receptor inhibitor are the same as those described above.
[0041] (Second embodiment) In one embodiment, the present invention provides (ix) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 5, or (x) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 5 in which 1 to 3 amino acids have been deleted, substituted, or added, and which is an ApoE - / - The present invention provides a method for screening therapeutic agents for arteriosclerosis, which comprises the steps of culturing vascular endothelial cells or macrophage cells in the presence of a peptide having an activity of promoting arteriosclerosis when administered to mice and a test substance, and measuring the expression level of inflammatory cytokines or arteriosclerosis-promoting factors in the cells, wherein a significant decrease in the expression level compared to that in the absence of the test substance indicates that the test substance is an agent for treating arteriosclerosis.
[0042] As described later in the Examples, the inventors have demonstrated that GIP_HUMAN[22-51] (SEQ ID NO: 5) acts on vascular smooth muscle cells, vascular endothelial cells, or macrophages to induce the expression of inflammatory cytokines and pro-atherogenic factors through activation of NF-κB signaling. Therefore, a test substance that inhibits the induction of the expression of these factors can be used as a therapeutic agent for atherosclerosis.
[0043] That is, the present invention provides a method for screening for therapeutic agents for arteriosclerosis, which comprises the steps of culturing vascular smooth muscle cells, vascular endothelial cells, or macrophage cells in the presence of GIP_HUMAN[22-51] (SEQ ID NO: 5) or its mutant peptide and a test substance, and measuring the expression level of inflammatory cytokines or pro-arteriosclerosis factors in the cells, wherein a significant decrease in the expression level compared to that in the absence of the test substance indicates that the test substance is a therapeutic agent for arteriosclerosis. The method of the second embodiment can also be used to screen for therapeutic agents for arteriosclerosis.
[0044] The test substances are the same as those described above. Examples of inflammatory cytokines, chemokines, and arteriosclerosis-promoting factors include angiopoietin 2 (Angpt2), angiopoietin 3 (Angpt3), serum amyloid P (SAP), CXCL16, PCSK9, fetuin A, cystatin C, low-density lipoprotein receptor (LDLR), MMP-3, IGF-binding protein (IGFBP), vascular cell adhesion molecule-1 (VCAM1), intercellular adhesion molecule-1 (ICAM1), and endostatin.
[0045] [Arteriosclerosis treatment] In one embodiment, the present invention provides (ix) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 5, or (x) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 5 in which 1 to 3 amino acids have been deleted, substituted, or added, and which is an ApoE - / -The present invention provides a therapeutic agent for arteriosclerosis, which contains as an active ingredient an antibody or a fragment thereof against a peptide that has the activity of promoting arteriosclerosis when administered to mice.
[0046] As described later in the Examples, the inventors administered an antibody against GIP_HUMAN[22-51] (SEQ ID NO: 5) to a mouse model of atherosclerosis, ApoE - / - It was revealed that when administered to mice, arteriosclerosis was significantly suppressed.
[0047] Therefore, the above-mentioned antibody or a fragment thereof can be used as a therapeutic agent for arteriosclerosis. The antibody is preferably a human antibody. The antibody fragment and human antibody are the same as those described above.
[0048] [Other embodiments] (Treatment method for type 2 diabetes) In one embodiment, the present invention provides a method for treating type 2 diabetes, comprising administering to a patient in need of treatment an effective amount of (i) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1, (ii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1 with one to three amino acids deleted, substituted, or added, and which has the activity of suppressing food intake or water drinking when administered to a mammal, (iii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 2, or (iv) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 2 with one to three amino acids deleted, substituted, or added, and which has the activity of suppressing food intake or water drinking when administered to a mammal. The treatment method of this embodiment can also be said to be a method of suppressing food intake or water drinking in a patient.
[0049] In one embodiment, the present invention provides (i) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1, (ii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1 in which 1 to 3 amino acids have been deleted, substituted or added, and which has the activity of suppressing food intake or water drinking when administered to a mammal, (iii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 2, or (iv) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 2 in which 1 to 3 amino acids have been deleted, substituted or added, and which has the activity of suppressing food intake or water drinking when administered to a mammal, all of which are used in the treatment of type 2 diabetes.
[0050] In one embodiment, the present invention provides use of (i) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1; (ii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1 in which 1 to 3 amino acids have been deleted, substituted or added, and which has the activity of suppressing food intake or water drinking when administered to a mammal; (iii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 2; or (iv) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 2 in which 1 to 3 amino acids have been deleted, substituted or added, and which has the activity of suppressing food intake or water drinking when administered to a mammal, for the manufacture of a therapeutic agent for type 2 diabetes.
[0051] (Method for treating inflammatory diseases or tumors) In one embodiment, the present invention provides a method for treating an inflammatory disease or tumor, comprising administering to a patient in need of treatment an effective amount of an antibody or a fragment thereof against: (v) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 3; (vi) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 3 with one to three amino acids deleted, substituted, or added, and which has the activity of inducing the expression of inflammatory cytokines, chemokines, cell growth factors, or angiogenesis promoting factors through the activation of NF-κB signaling when contacted with vascular smooth muscle cells, vascular endothelial cells, or macrophage cells; (vii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4; or (viii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4 with one to three amino acids deleted, substituted, or added, and which has the activity of inducing the expression of inflammatory cytokines, chemokines, cell growth factors, or angiogenesis promoting factors through the activation of NF-κB signaling when contacted with vascular smooth muscle cells, vascular endothelial cells, or macrophage cells.
[0052] Inflammatory diseases include rheumatoid arthritis, cytokine storms such as COVID-19 severe pneumonia, etc. The tumor is not particularly limited as long as it is a tumor accompanied by angiogenesis.
[0053] In one embodiment, the present invention provides an antibody or a fragment thereof for use in the treatment of an inflammatory disease or tumor: (v) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 3; (vi) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 3 in which 1 to 3 amino acids have been deleted, substituted, or added, and which has the activity of inducing the expression of pro-inflammatory cytokines, chemokines, cell growth factors, or angiogenesis promoting factors through the activation of NF-κB signaling when contacted with vascular smooth muscle cells, vascular endothelial cells, or macrophage cells; (vii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4; or (viii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4 in which 1 to 3 amino acids have been deleted, substituted, or added, and which has the activity of inducing the expression of pro-inflammatory cytokines, chemokines, cell growth factors, or angiogenesis promoting factors through the activation of NF-κB signaling when contacted with vascular smooth muscle cells, vascular endothelial cells, or macrophage cells.
[0054] In one embodiment, the present invention provides use of an antibody or a fragment thereof against (v) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 3; (vi) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 3 in which 1 to 3 amino acids have been deleted, substituted, or added, and which has the activity of inducing the expression of pro-inflammatory cytokines, chemokines, cell growth factors, or pro-angiogenic factors through the activation of NF-κB signaling when contacted with vascular smooth muscle cells, vascular endothelial cells, or macrophage cells; (vii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4; or (viii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4 in which 1 to 3 amino acids have been deleted, substituted, or added, and which has the activity of inducing the expression of pro-inflammatory cytokines, chemokines, cell growth factors, or pro-angiogenic factors through the activation of NF-κB signaling when contacted with vascular smooth muscle cells, vascular endothelial cells, or macrophage cells, for the manufacture of a therapeutic agent for an inflammatory disease or tumor.
[0055] (Treatment method for arteriosclerosis) In one embodiment, the present invention provides (ix) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 5, or (x) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 5 in which 1 to 3 amino acids have been deleted, substituted, or added, and which is an ApoE - / - The present invention provides a method for treating arteriosclerosis, which comprises administering to a patient in need of treatment an effective amount of an antibody or a fragment thereof against a peptide that has the activity of promoting arteriosclerosis when administered to mice.
[0056] In one embodiment, the present invention relates to (ix) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 5, or (x) an amino acid sequence in which 1 to 3 amino acids are deleted, substituted, or added in the amino acid sequence set forth in SEQ ID NO: 5, and which is used for the treatment of arteriosclerosis, and which is an ApoE - / - The present invention provides an antibody or a fragment thereof against a peptide that has the activity of promoting arteriosclerosis when administered to mice.
[0057] In one embodiment, the present invention relates to a peptide for producing a therapeutic agent for arteriosclerosis, comprising (ix) the amino acid sequence of SEQ ID NO: 5, or (x) the amino acid sequence of SEQ ID NO: 5 in which 1 to 3 amino acids are deleted, substituted, or added, and which is a peptide encoding ApoE - / - The present invention provides use of an antibody or a fragment thereof against a peptide that has the activity of promoting arteriosclerosis when administered to mice. [Example]
[0058] The present invention will now be described in more detail with reference to examples, but the present invention is not limited to the following examples.
[0059] [Experimental Example 1] The inventors have developed an improved differential solubilization method (see Non-Patent Document 2) to identify a large number of peptides present in human plasma. Among these, we focused on the peptides with amino acid sequences set forth in SEQ ID NOS: 1 to 5, and conducted the following experiments.
[0060] <Examination of SBSN_HUMAN[225-237] (SEQ ID NO: 3), SBSN_HUMAN[243-259] (SEQ ID NO: 4), and SBSN_HUMAN[279-295] (SEQ ID NO: 1)> [Experimental Example 2] (Examination of the binding of peptides to vascular smooth muscle cells) The binding of SBSN_HUMAN[225-237] (SEQ ID NO: 3), SBSN_HUMAN[243-259] (SEQ ID NO: 4), and SBSN_HUMAN[279-295] (SEQ ID NO: 1) to vascular smooth muscle cells was examined.
[0061] First, each peptide was chemically synthesized. A 5-carboxyfluorescein (FAM) label was attached to the N-terminus of each peptide. Subsequently, each peptide was added to the medium of HAoSMC, a human vascular smooth muscle cell line, to a final concentration of 1 μM, and the presence or absence of binding to the cell surface was evaluated using a plate reader and a confocal microscope.
[0062] Figure 1(a) is a graph showing the results of measuring the binding of SBSN_HUMAN[225-237] (SEQ ID NO: 3) to vascular smooth muscle cells by detecting the fluorescence of FAM using a plate reader.
[0063] Figure 1(b) is a graph showing the results of measuring the binding of SBSN_HUMAN[243-259] (SEQ ID NO: 4) to vascular smooth muscle cells by detecting the fluorescence of FAM using a plate reader.
[0064] As a result, it was revealed that the fluorescence intensity of SBSN_HUMAN[225-237] (SEQ ID NO: 3) and SBSN_HUMAN[243-259] (SEQ ID NO: 4) increased rapidly within 30 minutes after addition to the cell medium, and the binding was then maintained. On the other hand, it was revealed that SBSN_HUMAN[279-295] (SEQ ID NO: 1) did not show binding to vascular smooth muscle cells.
[0065] Figures 1(c) to (f) are confocal micrographs taken. Figure 1(c) is a control where no peptide was added, Figure 1(d) shows the results when SBSN_HUMAN[225-237] (SEQ ID NO: 3) was added to the medium, Figure 1(e) shows the results when SBSN_HUMAN[243-259] (SEQ ID NO: 4) was added to the medium, and Figure 1(f) shows the results when SBSN_HUMAN[279-295] (SEQ ID NO: 1) was added to the medium. As a result, FAM fluorescence was observed in Figures 1(d) and (e), but no fluorescence was observed in Figure 1(f).
[0066] These results demonstrate that SBSN_HUMAN[225-237] (sequence number 3) and SBSN_HUMAN[243-259] (sequence number 4) bind to vascular smooth muscle cells, while SBSN_HUMAN[279-295] (sequence number 1) does not bind to vascular smooth muscle cells.
[0067] [Experimental Example 3] (Examination of peptide functions) Human vascular smooth muscle cell line HAoSMCs were cultured until confluent and then further cultured in serum-free medium for 16 hours. Then, SBSN_HUMAN[225-237] (SEQ ID NO: 3) or SBSN_HUMAN[243-259] (SEQ ID NO: 4) was added to the medium to a final concentration of 0.1 μM, and the cells were cultured for 24 hours. The secretion levels of cytokines, chemokines, cell growth factors, and cell death-related factors expressed in the culture supernatant were evaluated using a commercially available kit (product name: "Proteome Profiler Human XL Cytokine Arrays"; R&D Systems).
[0068] Figure 2(a) shows the results of adding SBSN_HUMAN[225-237] (SEQ ID NO: 3) to the medium. The table in Figure 2(a) shows the relative increase in secretion for the top five factors with increased secretion. Figure 2(b) shows the results of adding SBSN_HUMAN[243-259] (SEQ ID NO: 4) to the medium. The table in Figure 2(b) shows the relative increase in secretion for the top five factors with increased secretion.
[0069] As a result, it was revealed that SBSN_HUMAN[225-237] (sequence number 3) significantly promoted the secretion of potent cytokines, chemokines, growth factors, angiogenesis-promoting factors, and apoptosis-regulating factors, including VEGFa, DKK1, Endoglin, uPAR, and cystatin C.
[0070] Furthermore, it was revealed that SBSN_HUMAN[243-259] (SEQ ID NO: 4) promoted the secretion of HGF, VEGFα, DKK1, OPN, interleukin-6 (IL-6), and the like.
[0071] From the above results, it was revealed that SBSN_HUMAN[225-237] (sequence number 3) and SBSN_HUMAN[243-259] (sequence number 4) have strong inflammation-inducing, cell proliferation-promoting, and arteriosclerosis-promoting effects on vascular smooth muscle cells.
[0072] [Experimental Example 4] (Study of peptide-mediated signal transduction mechanisms) SBSN_HUMAN[225-237] (SEQ ID NO: 3) or SBSN_HUMAN[243-259] (SEQ ID NO: 4) was added to the culture medium of HAoSMC, a human vascular smooth muscle cell line, and IκB-α degradation and NF-κB p65 localization were examined. IκB-α degradation was examined by Western blotting. NF-κB p65 localization was examined by immunostaining.
[0073] Figure 3(a) is a photograph showing the results of Western blotting to detect the presence of IκB-α 0, 5, 10, 15, 30, and 60 minutes after adding SBSN_HUMAN[225-237] (SEQ ID NO: 3) to the culture medium of HAoSMCs. Also shown is the result of detecting β-actin as a loading control.
[0074] Figure 3(b) is a photograph showing the results of Western blotting to detect the presence of IκB-α at 0, 5, 10, 15, 30, and 60 minutes after adding SBSN_HUMAN[243-259] (SEQ ID NO: 4) to the culture medium of HAoSMCs. Also shown is the result of detecting β-actin as a loading control.
[0075] Figures 3(c) to (e) are fluorescent micrographs showing the results of detecting NF-κB p65 by immunostaining. Figure 3(c) is a photograph taken immediately (0 minutes) after adding the peptide to the HAoSMC culture medium. Figure 3(b) is a photograph taken 120 minutes after adding SBSN_HUMAN[225-237] (SEQ ID NO: 3) to the HAoSMC culture medium. Figure 3(c) is a photograph taken 120 minutes after adding SBSN_HUMAN[243-259] (SEQ ID NO: 4) to the HAoSMC culture medium. In Figures 3(b) and (c), the arrowheads indicate NF-κB p65 immunoreactivity in the cell nuclei.
[0076] The results showed that addition of either peptide resulted in the disruption of IκB-α and the translocation of NF-κB p65 into the nucleus.
[0077] These results demonstrate that SBSN_HUMAN[225-237] (SEQ ID NO: 3) and SBSN_HUMAN[243-259] (SEQ ID NO: 4) exhibit NF-κB activation promoting activity. This suggests that NF-κB activation is involved in the induction of various cytokines, chemokines, growth factors, angiogenesis control factors, and the like, as shown in Experimental Example 3.
[0078] [Experimental Example 5] (Study of peptide-mediated signal transduction mechanisms) To clarify whether NF-κB is directly involved in the induction of various cytokines, chemokines, growth factors, angiogenesis regulators, etc. by SBSN_HUMAN[225-237] (sequence number 3) and SBSN_HUMAN[243-259] (sequence number 4), the inhibitory effect of the proteasome inhibitor MG132 (CAS number: 133407-82-6) on VEGF expression was evaluated.
[0079] Human vascular smooth muscle cell line HAoSMCs were cultured until confluent and then further cultured in serum-free medium for 16 hours. MG132 was then added to the medium to a final concentration of 100 nM and pretreated for 30 minutes. Subsequently, SBSN_HUMAN[225-237] (SEQ ID NO: 3) or SBSN_HUMAN[243-259] (SEQ ID NO: 4) was added to a final concentration of 0.1 μM and cultured for 8 hours. VEGF gene expression was then assessed by quantitative RT-PCR.
[0080] Figure 4(a) and (b) show the results of quantitative RT-PCR performed when SBSN_HUMAN[225-237] (SEQ ID NO: 3) and SBSN_HUMAN[243-259] (SEQ ID NO: 4) were added to HAoSMC culture media.
[0081] 4(a) and (b), "-" indicates that MG132, SBSN_HUMAN[225-237] (SEQ ID NO: 3), or SBSN_HUMAN[243-259] (SEQ ID NO: 4) was not added to the medium, "+" indicates that MG132, SBSN_HUMAN[225-237] (SEQ ID NO: 3), or SBSN_HUMAN[243-259] (SEQ ID NO: 4) was added to the medium, and "**" indicates that there was a significant difference at p<0.01.
[0082] The results showed that pretreatment with MG132 significantly suppressed VEGF gene expression, indicating that NF-κB directly mediates the induction of various cytokines, chemokines, growth factors, and angiogenesis regulators by SBSN_HUMAN[225-237] (SEQ ID NO: 3) and SBSN_HUMAN[243-259] (SEQ ID NO: 4).
[0083] [Experimental Example 6] (Administration of peptide to mice) SBSN_HUMAN[279-295] (SEQ ID NO: 1) was administered to mice to examine its function. C57BL / 6 mice (male adult, Claire) were housed at 22–25°C under a 12-hour light / dark cycle with free access to food and water. They were fed a standard diet (CE2). After acclimation to intraperitoneal administration of saline for at least 7 days, SBSN_HUMAN[279-295] (SEQ ID NO: 1) was administered intraperitoneally 30 minutes before the onset of the dark period. Food intake, water intake, and activity during the dark period were monitored over time using a food intake, water intake, and activity monitoring system (product name: ACTIMO-100M, Shin Factory) under freely moving conditions. SBSN_HUMAN[279-295] (SEQ ID NO: 1) was administered at a dose of 10 pmol / mouse or 100 pmol / mouse.
[0084] Figures 5(a) to (f) are graphs showing the results of monitoring food intake, water intake, and activity. Figures 5(a) to (c) show the results of administering 10 pmol of SBSN_HUMAN[279-295] (SEQ ID NO: 1) per mouse, and Figures 5(d) to (f) show the results of administering 100 pmol of SBSN_HUMAN[279-295] (SEQ ID NO: 1) per mouse.
[0085] In addition, the vertical axis of Figures 5(a) and (d) represents food intake (g), and the horizontal axis represents time (minutes). In Figures 5(b) and (e), the vertical axis represents water intake (mL), and the horizontal axis represents time (minutes). In Figures 5(c) and (f), the vertical axis represents activity level (counts), and the horizontal axis represents time (minutes). In Figures 5(a) to (f), "vehicle" indicates that only purified water containing no peptide was administered. Furthermore, "*" indicates that there is a significant difference at p<0.05, and "**" indicates that there is a significant difference at p<0.01.
[0086] As a result, administration of only 10 pmol / mouse of SBSN_HUMAN[279-295] (SEQ ID NO: 1) significantly reduced food intake and water intake, indicating that SBSN_HUMAN[279-295] (SEQ ID NO: 1) is a potent endogenous factor that regulates food intake and water intake.
[0087] [Experimental Example 7] (Analysis of peptide expression in various major human organs) Rabbits were immunized with SBSN_HUMAN[225-237] (SEQ ID NO: 3), SBSN_HUMAN[243-259] (SEQ ID NO: 4), and SBSN_HUMAN[279-295] (SEQ ID NO: 1), respectively, to prepare polyclonal antibodies specific to each peptide.
[0088] Next, a commercially available human tissue array (catalog number "MNO341", US Biomax) was immunostained with each polyclonal antibody, and peptide expression in various major human organs was analyzed. The results are shown in Table 1 below. In Table 1, "-" indicates that no expression was observed, while "+" and "++" indicate that expression was observed. Furthermore, "++" indicates that the expression level was higher than "+".
[0089] [Table 1]
[0090] As a result, it was revealed that SBSN_HUMAN[243-259] (SEQ ID NO: 4) is not a peptide universally expressed in various tissues, but is specifically expressed in the liver and pancreas, whereas SBSN_HUMAN[225-237] (SEQ ID NO: 3) and SBSN_HUMAN[279-295] (SEQ ID NO: 1) are peptides universally expressed in many tissues.
[0091] [Experimental Example 8] (Analysis of peptide expression in various human cell lines) Peptide expression in various cultured human cells was analyzed by immunostaining using specific polyclonal antibodies against SBSN_HUMAN[225-237] (SEQ ID NO: 3), SBSN_HUMAN[243-259] (SEQ ID NO: 4), and SBSN_HUMAN[279-295] (SEQ ID NO: 1).
[0092] Figures 6(a) to (e), (a') to (e'), and (a'') to (e'') are fluorescent micrographs showing the results of immunostaining. Figures 6(a) to (e) show the results of staining with an antibody against SBSN_HUMAN[225-237] (SEQ ID NO: 3), (a') to (e') show the results of staining with an antibody against SBSN_HUMAN[243-259] (SEQ ID NO: 4), and (a'') to (e'') show the results of staining with an antibody against SBSN_HUMAN[279-295] (SEQ ID NO: 4). The antibody dilution ratio in all cases was 1000 times.
[0093] Figures 6(a), (a'), and (a'') show the staining results for HAoSMC, a human vascular smooth muscle cell line; Figures 6(b), (b'), and (b'') show the staining results for human monocyte THP-1-derived macrophages; Figures 6(c), (c'), and (c'') show the staining results for healthy human macrophages; Figures 6(d), (d'), and (d'') show the staining results for HaCaT, a human epidermal keratinocyte cell line; and Figures 6(e), (e'), and (e'') show the staining results for HepG2, a human liver cancer cell line. Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI).
[0094] As a result, it was revealed that all three types of peptides were expressed in cancer cells and macrophage cells.
[0095] <II. Examination of ANGT_HUMAN[448-462] (SEQ ID NO: 2)> [Experimental Example 9] (Examination of the binding of the peptide to macrophage cells) The binding of ANGT_HUMAN[448-462] (SEQ ID NO: 2) to macrophage cells was examined. First, the peptide was chemically synthesized. The N-terminus of the peptide was labeled with 5-carboxyfluorescein (FAM). Subsequently, the peptide was added to the medium of THP1 cells, which are a human monocyte cell line, at a final concentration of 1 μM and incubated for 60 minutes. Then, the presence or absence of binding to the cell surface was evaluated using a confocal microscope.
[0096] Also, for comparison, samples pretreated with β-casomorphin 5 at a final concentration of 10 μM or β-casomorphin 7 at a final concentration of 10 μM for 30 minutes were prepared. β-Casomorphin 5 and β-casomorphin 7 are known to be ligands of the β-chain of ATP synthase. At the same time, immunostaining of the α-chain and β-chain of ATP synthase was also performed.
[0097] Figures 7(a) to (f) are the photographed confocal microscopy images. Figures 7(a) to (c) are the results of immunostaining of the α-chain of ATP synthase, and Figures 7(d) to (f) are the results of immunostaining of the β-chain of ATP synthase.
[0098] Figures 7(b) and (e) are the results of pretreatment with β-casomorphin 5, which is considered to show a partial inhibitory effect on the α-chain of ATP synthase, before administration of FAM-labeled ANGT_HUMAN[448-462]. Figures 7(c) and (f) are the results of pretreatment with β-casomorphin 7, which is considered to show a competitive inhibitory effect on the α-chain of ATP synthase. Figures 7(a) and (d) are the results without pretreatment.
[0099] In Figures 7(a) to (f), the leftmost photograph is the result of staining the ATP synthase α chain (Figures 7(a) to (c)) or the ATP synthase β chain (Figures 7(d) to (f)), the second photograph from the left is the result of detecting fluorescence due to binding of FAM-labeled ANGT_HUMAN[448-462] (sequence number 2) to cells, the third photograph from the left is the result of staining the nucleus with DAPI, and the rightmost photograph is a composite of the first to third photographs from the left.
[0100] As a result, it was revealed that ANGT_HUMAN[448-462] (SEQ ID NO: 2) colocalizes with the α- and β-chains of ATP synthase, which are known to bind and act as anti-angiogenic factors. Furthermore, it was revealed that the binding of ANGT_HUMAN[448-462] (SEQ ID NO: 2) to the cell surface ATP synthase α- and β-chains is competitively inhibited by β-casomorphin 5 and β-casomorphin 7.
[0101] [Experimental Example 10] (Administration of peptide to mice 1) ANGT_HUMAN[448-462] (SEQ ID NO: 2) was administered to mice to examine its function. C57BL / 6 mice (male adult, Claire) were housed at 22–25°C under a 12-hour light / dark cycle with free access to food and water. They were fed a standard diet (CE2). After acclimation to intraperitoneal administration of saline for at least 7 days, ANGT_HUMAN[448-462] (SEQ ID NO: 2) was administered intraperitoneally 30 min before the onset of the dark phase. Food intake, water intake, and activity during the dark phase were monitored over time using a food intake, water intake, and activity monitoring system (product name "ACTIMO-100M," Shin Factory) under freely moving conditions. ANGT_HUMAN[448-462] (SEQ ID NO: 2) was administered at a dose of 100 pmol per mouse.
[0102] Figures 8(a) to (c) are graphs showing the monitoring results of food intake, water intake, and activity level. In Figure 8(a), the vertical axis represents food intake (g), and the horizontal axis represents time (minutes). In Figure 8(b), the vertical axis represents water intake (mL), and the horizontal axis represents time (minutes). In Figure 8(c), the vertical axis represents activity level (counts), and the horizontal axis represents time (minutes). In Figures 8(a) to (c), "vehicle" indicates that only purified water containing no peptide was administered. Additionally, "*" indicates that there is a significant difference at p<0.05, and "**" indicates that there is a significant difference at p<0.01.
[0103] As a result, administration of only 100 pmol of ANGT_HUMAN[448-462] (SEQ ID NO: 2) per mouse significantly reduced food and water intake, indicating that ANGT_HUMAN[448-462] (SEQ ID NO: 2) is a potent peripheral inhibitor of food and water intake.
[0104] [Experimental Example 11] (Administration of peptide to mice 2) ANGT_HUMAN[448-462] (SEQ ID NO: 2) was administered to mice to examine its function. In Experiment 10, it was administered intraperitoneally, whereas in this experiment, it was administered intracerebroventricularly. C57BL / 6 mice (adult males, Claire) were housed at 22-25°C under a 12-hour light-dark cycle with free access to food and water. They were fed a standard diet, CE2. ANGT_HUMAN[448-462] (SEQ ID NO: 2) was administered intracerebroventricularly through an implanted intracerebroventricular catheter, and food intake, water intake, and activity during the dark phase were monitored over time using a food intake, water intake, and activity monitoring system (product name "ACTIMO-100M", Shin Factory) under freely moving conditions. ANGT_HUMAN[448-462] (SEQ ID NO: 2) was administered at a dose of 1 pmol / mouse.
[0105] Figures 9(a) to (c) are graphs showing the monitoring results of food intake, water intake, and activity level. The vertical axis of Figure 9(a) indicates food intake (g), and the horizontal axis indicates time (hours). The vertical axis of Figure 9(b) indicates water intake (mL), and the horizontal axis indicates time (hours). The vertical axis of Figure 9(c) indicates activity level (count), and the horizontal axis indicates time (hours). In Figures 9(a) to (c), "vehicle" indicates administration of purified water without the peptide. Also, "*" indicates the presence of a significant difference at p < 0.05.
[0106] As a result, only by administering ANGT_HUMAN[448 - 462] (SEQ ID NO: 2) at a mere 1 pmol / mouse, a significant decrease in food intake and water intake was observed. This result further supports that ANGT_HUMAN[448 - 462] (SEQ ID NO: 2) is a potent central feeding and drinking inhibitory factor. Also, since ANGT_HUMAN[448 - 462] (SEQ ID NO: 2) shows an effect at a very low concentration, it may have an effect of reducing food intake and water intake by oral administration.
[0107] <III. Examination of GIP_HUMAN[22 - 51] (SEQ ID NO: 5)> [Experimental Example 12] (Examination of Peptide Binding to Cells) The binding of GIP_HUMAN[22 - 51] (SEQ ID NO: 5) to vascular endothelial cells and macrophage cells was examined. First, the peptide was chemically synthesized. The N-terminus of the peptide was labeled with 5-carboxyfluorescein (FAM). Subsequently, the peptide was added to the medium of HAoEC, a human aortic endothelial cell line, at a final concentration of 1 μM and incubated for 30 minutes, after which the presence or absence of binding to the cell surface was evaluated using a confocal microscope. Also, the nuclei were stained with DAPI.
[0108] Figures 10(a) and (b) are the photographed confocal microscope images. Figure 10(a) is the result without reacting the peptide, and Figure 10(b) is the result after reacting the peptide. As a result, it became clear that GIP_HUMAN[22 - 51] (SEQ ID NO: 5) binds to vascular endothelial cells.
[0109] Next, FAM-labeled GIP_HUMAN[22-51] (SEQ ID NO: 5) was added to the culture medium of macrophage cells derived from human monocyte cell line THP1 cells at a final concentration of 1 μM and incubated for 5 minutes. After incubation, cell surface binding was evaluated using a confocal microscope. Nuclei were stained with DAPI.
[0110] Figures 10(c) and (d) are confocal micrographs. Figure 10(c) shows the results without peptide reaction, and Figure 10(d) shows the results with peptide reaction. The results demonstrated that GIP_HUMAN[22-51] (SEQ ID NO: 5) binds to macrophage cells.
[0111] [Experimental Example 13] (Study of peptide-mediated signal transduction mechanisms) GIP_HUMAN[22-51] (SEQ ID NO: 5) was contacted with human aortic endothelial cells and human macrophage cells to examine the translocation of NF-κB p65 to the nucleus.
[0112] The peptides were added to the culture medium of HAoEC, a human aortic endothelial cell line, or macrophage cells derived from THP1 cells, a human monocyte cell line, at a final concentration of 1 μM and incubated for 60 minutes, after which NF-κB p65 was stained by immunostaining.
[0113] Figures 11(a) and (b) are photographs showing the results for aortic endothelial cells. Figure 11(a) shows the results when no peptide was added, and Figure 11(b) shows the results when GIP_HUMAN[22-51] (SEQ ID NO: 5) was added. The results demonstrated that the addition of GIP_HUMAN[22-51] (SEQ ID NO: 5) to the culture medium of aortic endothelial cells resulted in the translocation of NF-κB to the nucleus.
[0114] Figures 11(c) and (d) are photographs showing the results for macrophage cells. Figure 11(c) shows the results when no peptide was added, and Figure 11(d) shows the results when GIP_HUMAN[22-51] (SEQ ID NO: 5) was added. The results demonstrated that the addition of GIP_HUMAN[22-51] (SEQ ID NO: 5) to the culture medium of macrophage cells resulted in the translocation of NF-κB to the nucleus.
[0115] [Experimental Example 14] (Study of effects on arteriosclerosis) The effect of GIP_HUMAN[22-51] (SEQ ID NO: 5) on arteriosclerosis was examined. - / - Mice (17 weeks old) were administered GIP_HUMAN[22-51] (SEQ ID NO: 5) or saline for 4 weeks using an osmotic pump, and the progression of atherosclerosis was evaluated. The effect of administering a polyclonal antibody against GIP_HUMAN[22-51] (SEQ ID NO: 5) was also examined. The polyclonal antibody was produced by immunizing rabbits with GIP_HUMAN[22-51] (SEQ ID NO: 5).
[0116] Figures 12(a)-(d) show macroscopic tissue specimens showing the results of the study, and (e)-(l) are micrographs. Figures 12(a), (e), and (i) show the results of administering saline alone. Figures 12(b), (c), (f), (g), (j), and (k) show the results of administering GIP_HUMAN[22-51] (SEQ ID NO: 5) at a dose of 0.6 nM / kg / hour. Figures 12(c), (d), (g), (h), (k), and (l) show the results of administering an antibody against GIP_HUMAN[22-51] (SEQ ID NO: 5) at a dose of 1.4 μg / kg / hour.
[0117] Figures 12(a), (b), (c), and (d) show the results of Oil Red O staining of the aortic surface. Figures 12(e), (f), (g), and (h) show the results of Oil Red O staining of a cross section of the aortic root. Figures 12(i), (j), (k), and (l) show the results of staining with anti-MOMA-2 antibody. Anti-MOMA-2 antibody binds to monocytes and macrophages.
[0118] As a result, it was revealed that administration of GIP_HUMAN[22-51] (SEQ ID NO: 5) accelerates the progression of arteriosclerosis, and that administration of an antibody against GIP_HUMAN[22-51] (SEQ ID NO: 5) can suppress this progression.
[0119] Subsequently, ApoE mice were administered GIP_HUMAN[22-51] (SEQ ID NO: 5) for 4 weeks. - / - Mice and ApoE mice administered GIP_HUMAN[22-51] (SEQ ID NO: 5) and antibodies against GIP_HUMAN[22-51] (SEQ ID NO: 5) for 4 weeks - / - Cytokines and chemokines in mouse serum were quantified using a commercially available antibody array (product name: "Mouse XL Cytokine Kit", R&D Systems).
[0120] Figure 13(a) shows the relative abundance of cytokines and chemokines in the serum of mice administered GIP_HUMAN[22-51] (SEQ ID NO: 5). Figure 13(b) shows the relative abundance of cytokines and chemokines in the serum of mice administered GIP_HUMAN[22-51] (SEQ ID NO: 5) and antibodies against GIP_HUMAN[22-51] (SEQ ID NO: 5).
[0121] As a result, it was revealed that administration of GIP_HUMAN[22-51] (sequence number 5) increased serum levels of inflammatory cytokines and atherosclerosis-promoting factors such as angiopoietin 2 (Angpt2), serum amyloid P (SAP), CXCL16, PCSK9, fetuin A, and MMP-3.
[0122] On the other hand, it was revealed that administration of antibodies against GIP_HUMAN[22-51] (SEQ ID NO: 5) reduced serum levels of ICAM-1, VCAM-1, fetuin A, PCSK9, CXCL16, SAP, and the like.
[0123] The above results indicate that GIP_HUMAN[22-51] (SEQ ID NO: 5) is an endogenous inducer of inflammatory cytokines, chemokines and pro-atherogenic factors. [Industrial Applicability]
[0124] The present invention provides novel physiologically active peptides present in human blood. More specifically, it provides anti-obesity drugs; inducers of inflammatory cytokines, chemokines, cell growth factors, or angiogenesis-promoting factors through activation of NF-κB signaling in vascular smooth muscle cells, vascular endothelial cells, or macrophages; methods for screening therapeutic agents for inflammatory diseases or tumors; therapeutic agents for inflammatory diseases or tumors; and agents for promoting and treating arteriosclerosis.
Claims
[Claim 1] An anti-obesity drug having as an active ingredient a peptide consisting of the amino acid sequence set forth in SEQ ID NO:1.
Citation Information
Patent Citations
Compositions and methods for treating immune-related diseases
JP2004516227A
